---
title: "Wegovy (semaglutide), all indications: Pharmacology questions"
description: "Pharmacology questions on Wegovy (semaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Wegovy work for weight loss (mechanism of action)? Does Wegovy cause more fat loss than muscle (lean mass) loss? How long does Wegovy stay in your system (half-life)? How is Wegovy metabolized and eliminated? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide), all indications: Pharmacology questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)

## Mechanism

<a id="wegovy-mechanism"></a>

### How does Wegovy work for weight loss (mechanism of action)?

> “Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts 
> as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for 
> native GLP-1.
> GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present 
> in several areas of the brain involved in appetite regulation. Animal studies show that semaglutide 
> distributed to and activated neurons in brain regions involved in regulation of food intake.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “Semaglutide 
> decreases calorie intake. The effects are likely mediated by affecting appetite.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “Semaglutide delays gastric emptying.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “The effect of Wegovy<sup>®</sup> was studied in animal models. The impact of Wegovy<sup>®</sup> in the brain is not fully understood.”

Source: [WEGOVY: Wegovy® Mechanism of Action, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/about-wegovy/how-wegovy-works.html#:~:text=The%20effect%20of,brain%20is%20not%20fully%20understood.)

<a id="wegovy-fat-vs-muscle"></a>

### Does Wegovy cause more fat loss than muscle (lean mass) loss?

> “Semaglutide lowers body weight with greater fat mass loss than lean mass loss.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

## Pharmacokinetics

<a id="wegovy-half-life"></a>

### How long does Wegovy stay in your system (half-life)?

> “With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation 
> for about 5 to 7 weeks after the last injectable dose of 2.4 mg or 7.2 mg or oral dose of 25 mg.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

<a id="wegovy-metabolism"></a>

### How is Wegovy metabolized and eliminated?

> “Metabolism: The primary route of elimination for semaglutide is metabolism following proteolytic 
> cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid sidechain.
> Excretion: The primary excretion routes of semaglutide-related material are via the urine and feces. 
> Approximately 3% of the dose is excreted in the urine as intact semaglutide.”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

## Components

<a id="wegovy-inactive-ingredients"></a>

### What are the inactive ingredients in Wegovy?

> “Each 1 mL of WEGOVY<sup>®</sup> contains the following 
> inactive ingredients: disodium phosphate dihydrate, 1.42 mg; sodium chloride, 8.25 mg; and water 
> for injection. WEGOVY<sup>®</sup> has a pH of approximately 7.4. Hydrochloric acid or sodium hydroxide may 
> be added to adjust pH.
> Each 3 mL prefilled single-patient-use pen contains semaglutide 9.6 mg (3.2 mg/mL), which provides 4 
> doses of 2.4 mg semaglutide per 0.75 mL. Each 1 mL of WEGOVY<sup>®</sup> FlexTouch<sup>®</sup> solution also contains 
> the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; phenol, 5.5 mg; propylene 
> glycol, 14 mg; and water for injections. WEGOVY<sup>®</sup> has a pH of approximately 7.4. Hydrochloric acid 
> or sodium hydroxide may be added to adjust pH.
> Each single-patient-use WEGOVY<sup>®</sup> FlexTouch<sup>®</sup> Pen contains additional volume to allow for device 
> priming.
> WEGOVY<sup>®</sup> tablets include semaglutide as a white to almost white hygroscopic powder. Each tablet of 
> WEGOVY<sup>®</sup> contains 1.5 mg, 4 mg, 9 mg or 25 mg of semaglutide and the following inactive ingredients: 
> magnesium stearate and salcaprozate sodium (SNAC).”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

## Related pages
- [Medical information: Wegovy (semaglutide): All indications](https://www.evicenter.com/medical-information/wegovy)
- [Indication](https://www.evicenter.com/medical-information/wegovy/indication)
- [Safety](https://www.evicenter.com/medical-information/wegovy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/wegovy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/wegovy/storage-and-supply)
